Search
Menu
Home
HTB
2017
August
01
HTB
1 August 2017
Contents
Hepatitis coinfection
FDA approves sofosbuvir/velpatasvir/voxilaprevir (Vosevi) second-line DAA HCV treatment in the US in the US